Feng Jiye, Wang Jinbo, Chen Mingliang, Chen Gun, Wu Zongyang, Ying Liping, Zhuo Qifeng, Zhang Jianlei, Wang Weilin
Department of Hepatobiliary Surgery, Ningbo Yinzhou People's Hospital (Yinzhou Hospital Affiliated to Medical School of Ningbo University), Ningbo, Zhejiang 315040, P.R. China.
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
Oncol Rep. 2015 Feb;33(2):713-20. doi: 10.3892/or.2014.3642. Epub 2014 Dec 2.
miR-200a suppresses tumor development and progression; however, its role in tumor growth and metastasis of hepatocellular carcinoma (HCC) and the underlying mechanism have not been elucidated. In the present study, we identified that miR-200a was markedly downregulated in HCC and exerted suppressive effects on tumor cell growth and metastasis. We identified that miR-200a suppressed tumor growth and metastasis by directly targeting MACC1. In addition, HCC patients with low miR-200a expression had significantly worse prognosis than those with high expression of miR-200a. These findings suggest that miR-200a may be recognized as a novel potential biomarker to predict the survival of patients with HCCs following liver transplantation.
微小RNA-200a（miR-200a）可抑制肿瘤的发生和发展；然而，其在肝细胞癌（HCC）肿瘤生长和转移中的作用及潜在机制尚未阐明。在本研究中，我们发现miR-200a在HCC中显著下调，并对肿瘤细胞的生长和转移发挥抑制作用。我们发现miR-200a通过直接靶向转移和侵袭性蛋白1（MACC1）来抑制肿瘤生长和转移。此外，miR-200a低表达的HCC患者预后明显差于miR-200a高表达的患者。这些发现表明，miR-200a可能被视为一种新型潜在生物标志物，用于预测肝移植后HCC患者的生存情况。
